SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dong, S. Articles by Tweardy, D. J. Search for Related Content PubMed PubMed Citation Articles by Dong, S. Articles by Tweardy, D. J. Related Collections Neoplasia Plenary Papers Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 April 2002, Vol. 99, No. 8, pp. 2637-2646 PLENARY PAPER Interactions of STAT5b-RAR, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways Shuo Dong and David J. Tweardy From the Section of Infectious Disease, Department of Medicine, Baylor College of Medicine, Houston, TX, and the Shanghai Institute of Hematology, Shanghai Rui-Jin Hospital, Shanghai, Peoples Republic of China.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Signal transducer and activator of transcription (STAT) 5b-retinoic acid receptor (RAR)  is the fifth fusion protein identified in acute promyelocytic leukemia (APL). Initially described in a patient with all-trans retinoic acid (ATRA)-unresponsive disease, STAT5b-RAR resulted from an interstitial deletion on chromosome 17. To determine the molecular mechanisms of myeloid leukemogenesis and maturation arrest in STAT5b-RAR+ APL and its unresponsiveness to ATRA, we examined the effect of STAT5b-RAR on the activity of myeloid transcription factors including RAR/retinoid X receptor (RXR) , STAT3, and STAT5 as well as its molecular interactions with the nuclear receptor corepressor, SMRT, and nuclear receptor coactivator, TRAM-1. STAT5b-RAR bound to retinoic acid response elements (RAREs) both as a homodimer and as a heterodimer with RXR and inhibited wild-type RAR/RXR transactivation. Although STAT5b-RAR had no effect on ligand-induced STAT5b activation, it enhanced interleukin 6-induced STAT3-dependent reporter activity, an effect shared by other APL fusion proteins including promyelocytic leukemia-RAR and promyelocytic leukemia zinc finger (PLZF)-RAR. SMRT was released from STAT5b-RAR/SMRT complexes by ATRA at 106 M, whereas TRAM-1 became associated with STAT5b-RAR at 107 M. The coiled-coil domain of STAT5b was required for formation of STAT5b-RAR homodimers, for the inhibition of RAR/RXR transcriptional activity, and for stability of the STAT5b-RAR/SMRT complex. Thus, STAT5b-RAR contributes to myeloid maturation arrest by binding to RARE as either a homodimer or as a heterodimer with RXR resulting in the recruitment of SMRT and inhibition of RAR/RXR transcriptional activity. In addition, STAT5b-RAR and other APL fusion proteins may contribute to leukemogenesis by interaction with the STAT3 oncogene pathway. (Blood. 2002;99:2637-2646) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Nonrandom chromosomal translocations play a critical role in the pathogenesis of human blood malignancies.1 Five different chromosomal translocations have been reported and characterized so far in acute promyelocytic leukemia (APL), a disease effectively treated by agents that target the resultant chimeric transcription factor.2-4 In the great majority of patients, there is a specific chromosomal translocation t(15;17)(q22;q21), which involves the PML (promyelocytic leukemia) gene located on chromosome 15 and the RARA (retinoic acid receptor ) gene located on chromosome 17.5,6 The wild-type PML is a component of a nuclear structure referred to as PML nuclear body or POD (PML oncogenic domain). Almost all patients with t(15;17) APL respond well to differentiation therapy with all-trans retinoic acid (ATRA).4 Several variant chromosomal translocations occur in a small subset of APLs. Two variant translocations that result in ATRA-responsive APL are t(5;17)(q35;q21) and t(11;17)(q13;q21), which involve the RAR locus and a known gene NPM (nucleophosmin) on chromosome 57 and NuMA (nuclear mitotic apparatus protein) on chromosome 11,8 respectively. One additional variant translocation t(11;17)(q23;q21) has been found that fuses the RAR locus with the PLZF (promyelocytic leukemia zinc finger) gene on chromosome 11q23.9 In contrast to patients with APL with t(15;17), t(5;17), and t(11;17), those with t(11;17)(q23;q21) have a poor response to ATRA.3 Very recently, a fifth fusion gene STAT5b-RARA has been identified in one patient with ATRA-unresponsive APL.10 This fusion gene occurred as a result of an interstitial deletion within chromosome 17 and represents the first stable chromosomal abnormality described in a malignancy that involves a member of the STAT protein family. Seven signal transducer and activator of transcription (STAT) proteins have been identified in mammalian cells, STAT1, 2, 3, 4, 5a, 5b, and 6; each is tyrosine-phosphorylated by JAKs following the binding of cytokine to its receptor.11 Thus far, more than 40 different polypeptide ligands have been shown to cause STAT protein activation.11,12 On tyrosine phosphorylation, STAT proteins form homodimers or heterodimers through reciprocal intermolecular interactions involving the SH2 domain of one STAT protein binding to the phosphorylated tyrosine of its partner. Dimerization is followed by rapid translocation to the nucleus, binding to target DNA, and induction of gene expression. STAT5 was originally identified in sheep as a prolactin-induced mammary gland transcription factor.13 STAT3 was originally termed acute-phase response factor (APRF) because it was first identified as a transcription factor that bound to interleukin 6 (IL-6)-responsive elements within the promoters of various acute-phase protein genes.14 STAT5a and STAT5b are encoded by 2 highly homologous genes located in close proximity to each other and to STAT3 on mouse chromosome 11 and human chromosome 17.15-17 STAT protein activation, especially STAT5 and STAT3, has been implicated in cell transformation and carcinogenesis. In addition to their constitutive activation in solid tumors, aberrant activation of STAT5 and STAT3 has been reported in a variety of hematopoietic cancers including acute and chronic myelogenous and lymphocytic leukemias and lymphomas.18 Retinoic acid receptor  is a member of a superfamily of nuclear hormone receptors, which affects many physiologic processes including differentiation and growth arrest of various cell types including hematopoietic cells.19 In normal myeloid cells, RAR dimerizes with retinoid X receptor  (RXR); the dimers bind to retinoic acid response elements (RAREs) located in promoter/enhancer regions of specific genes. Recent models suggests that in the absence of ligand (retinoic acid, RA), RAR/RXR heterodimers associate at a 1:1 ratio with nuclear receptor transcriptional repressor complex corepressor (CoR) composed of SMRT/NCoR, Sin3, and histone deacetylase (HDAC) resulting in repression of basal transcription.20,21 Physiologic levels of RA induce dissociation of the CoR complex followed by recruitment of the transcriptional activation complex coactivator (CoA), consisting of CBP/p300, P/CAF, SRC-1, TIF2 (GRIP1/SRC-2), and p/CIP (TRAM-1/ACTR/AIB1/RAC3/SRC-3). Binding of the CoA complex results in the activation of gene expression and normal differentiation.22-24 In ATRA-responsive APL with t(15;17), the PML-RAR fusion protein binds RARE as a homodimer and recruits 2 CoR complexes with higher affinity than wild-type RAR.25,26 Complete dissociation of CoR from PML-RAR does not occur at physiologic levels of RA, but rather requires higher levels of ligand achieved during treatment with ATRA.25 Several hypotheses have been proposed to explain ATRA unresponsiveness in some variant APL including altered stoichiometry and stability of the CoR-fusion protein interaction26,27 and resistance of the APL-fusion gene products to ATRA-induced proteolysis.28 The molecular bases for leukemogenesis, arrested differentiation, and ATRA unresponsiveness in STAT5b-RAR+ APL are unknown. To address these issues, we examined the effect of STAT5b-RAR on myeloid leukemogenic and differentiation pathways involving RAR/RXR, STAT3 and STAT5 as well as the interaction between STAT5b-RAR and the nuclear receptor coregulators, CoR and CoA. We determined that STAT5b-RAR binds RARE as either a homodimer or as a heterodimer with RXR and modulates the transcriptional activities of RAR/RXR and STAT3 but not STAT5. STAT5b-RAR was insensitive to ATRA-induced proteolysis in transient expression COS-7 and HeLa cells. Finally, the ability of STAT5b-RAR to enhance STAT3 activity is shared by other APL fusion proteins including PML-RAR and PLZF-RAR and may therefore represent an important new pathway contributing to leukemogenesis in APL.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Cell lines and reagents COS-7, 293T, HepG2, and HeLa cells were cultured in Dulbecco modified Eagle medium (DMEM; Life Technologies, Grand Island, NY) with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 U/mL). Human IL-2 and IL-6 were purchased from Roche Molecular Biochemicals (Indianapolis, IN) and R & D Systems (Minneapolis, MN), respectively. ATRA was obtained from Sigma (St Louis, MO) and the ovine prolactin (NIDDK-oPRL-20) was obtained from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; Bethesda, MD). Plasmids The PML-RAR, PLZF-RAR, PLZF, RAR, and RXR expression vectors were described previously.29-31 The (RARE)3-tk-luciferase reporter5 and the APRE-luciferase reporter construct,32 which has 4 copies of acute phase response elements (APREs) were kindly provided by Dr A. Dejean (Paris, France) and Dr I. Matsumura (Osaka, Japan), respectively. The -casein luciferase reporter gene is from -casein gene promoter region (2300 to +490; a gift from Dr J. Rosen, Houston, TX).33 The human expression vectors for STAT5b, IL-2-receptor (IL-2R)  chain and  common chain were provided by Dr W. J. Leonard (National Institutes of Health [NIH], Bethesda, MD).16,34-36 The human JAK3 and the Nb2 PRL-R expression vector are from Dr O'Shea (NIH) and Dr L. Yu-Lee (Houston, TX), respectively. GST-TRAM-1 (residues 577-821) in pGEX-5X-2 and GST-SMRT (residues 983-1172) in pGEX-5X-1 both containing the receptor interaction domain were produced by polymerase chain reaction (PCR) with pfu DNA polymerase (Stratagene, La Jolla, CA) using TRAM-1 expression vector (kindly provided by Dr W. W. Chin, Boston, MA)24 and SMRT expression vector20 as template, respectively. The STAT5b-RAR (in pSG5 vector) (Stratagene) expression vectors was constructed by fusing human STAT5b16 and RAR using fusion-PCR technology37 based on the published sequence.10 A similar PCR approach also is applied to construct a series of mutant STAT5b-RARs, STAT5b-RAR(N), STAT5b-RAR(CC), and STAT5b-RAR(DBD). All plasmid constructs were confirmed by DNA sequencing and by in vitro translation and immunoblotting. Cell transfections For transient transfections, COS-7 and 293T cells were grown in 6-well (35-mm diameter) tissue culture plates to 50% to 80% confluence. Twelve hours later, the cells were transiently transfected with the indicated expression vectors and reporter genes by standard calcium phosphate coprecipitation method.38 The amounts of plasmid DNA used per well were 1 µg reporter vector, 1 to 4 µg expression vector, and 1 µg -galactosidase expression vector (Promega, Madison, WI) as transfection control. For HepG2 and HeLa cell, the GeneJuice transfection reagent (Novagen, Madison, WI) was used according to the manufacturer's instruction. Luciferase activity was measured in a luminometer (Luminoskan Ascent, Labsystems, Franklin, MA), expressed in arbitrary units and normalized according to the internal control. Each point is the mean of at least 3 independent experiments. In vitro translation The TNT-coupled rabbit reticulocyte lysate (Promega) system was used for in vitro translated proteins according to the manufacturer's instructions. The relative quantity of in vitro translated proteins was estimated as described.30,31 Briefly, parallel translation reactions were performed in the presence of [-35S] methionine (NEN, Boston, MA) and the proteins were visualized by autoradiography after separation on a 10% sodium dodecyl sulfate-polyacrylamide gel. Gel-shift DNA-binding assays The 293T, COS-7 and HepG2 cell lines were transiently transfected in 6-well plates using 2 to 4 µg plasmids. Forty-eight hours later, cells were either not treated or treated for 30 minutes with cytokines, IL-2 (50 ng/mL), prolactin (500 ng/mL), IL-6 (25 ng/mL), and the whole cell extracts (WCEs) were prepared as reported previously.39 About 20 µg WCE was incubated with duplex oligonucleotides in binding buffer (13 mM Hepes, pH 8.0, 65 mM NaCl, 1 mM DTT, 0.14 mM EDTA, 8% glycerol) and separated on 5% polyacrylamide gels. Duplex oligonucleotide probes included the high-affinity serum-inducible element (hSIE), prolactin response element (PRE) contained within the -casein promoter,13 and the APRE, an IL-6 response element within the rat 2-macroglobulin promoter.32 For supershift, 1 µg antibody was included in this reaction system when needed. Gel shift assays using in vitro protein were performed as described previously.30 Briefly, in vitro translated proteins were preincubated for 15 minutes at room temperature in the following buffer: 20 mM Hepes, pH 7.4, 50 mM KCl, 1 mM 2-mercaptoethanol, 10% glycerol, 1 µg poly (dI-dC) (Pharmacia), and 100 µg bovine serum albumin (BSA). [-32P] adenosine triphosphate (ATP; NEN) end-labeled duplex oligonucleotide probe was added and samples incubated at room temperature for 30 minutes and at 4°C for 30 minutes. Protein-DNA complexes were separated on 6% polyacrylamide gels equilibrated in 0.25 times tris-borate-EDTA buffer (TBE). Gels were dried, exposed to PhosphorImager plates and images developed and quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) and ImageQuant software. In vitro protein-binding assays The SMRT protein was expressed in Escherichia coli DH5 as a GST fusion product and purified by standard methodology. Twelve microliters of -35S] methionine-labeled in vitro translated proteins (STAT5b-RAR or STAT5b-RAR [CC]) was incubated with 1 µg GST-SMRT fusion protein conjugated to glutathione Sepharose (Amersham-Pharmacia Biotech, Piscataway, NJ) in binding buffer (20 mM Tris, pH 8.0, 150 mM KCl, 1 mM EDTA, 4 mM MgCl2, 0.2% NP-40, 10% glycerol) at 4°C for 2 hours without or with ATRA (Sigma). Bound proteins were washed 3 times with binding buffer, eluted by boiling in sample buffer, and resolved by 10% SDS-polyacrylamide gel electrophoresis (PAGE). Gels were dried, exposed, and analyzed by PhosphorImager. For in vitro coimmunoprecipitation, in vitro translated SMRT protein was incubated with 35S-labeled proteins, PLZF, RAR, and STAT5b, respectively, in binding buffer for 1 hour at 4°C. Immune complexes were isolated by further incubation with SMRT antibody presorbed on protein A/G (Santa Cruz Biotechnology, Santa Cruz, CA), washed 3 times in binding buffer and analyzed by SDS-PAGE. Immunoblotting Whole cell lysates were prepared in lysis buffer (20 mM Hepes, pH 7.9, 420 mM NaCl, 20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol [DTT], 20% glycerol, 0.5 mM phenylmethylsulfonyl fluoride [PMSF]). Equivalent amounts of total cellular protein were electrophoresed on 7.5% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride (PVDF) membrane (Millipore). Probing of PVDF membranes with primary antibodies and detection of horseradish peroxidase-conjugated secondary antibodies by enhanced chemiluminescence as directed (Amersham-Pharmacia Biotech). Antibodies used in this study are as follows: antihuman-RAR (C-20) antihuman-STAT5b (N-20), antihuman-STAT5b (C-17), and antihuman-SMRT (N-20), all from Santa Cruz Biotechnology, and antihuman--actin (monoclonal; Sigma).     Results Top Abstract Introduction Materials and methods Results Discussion References STAT5b-RAR binds RARE as a homodimer and preferentially as a heterodimer with RXR The APL fusion proteins previously identified and characterized contribute to leukemogenesis by binding to RAREs either as homodimers or heterodimers with RXR, thereby repressing gene transcription essential for myeloid differentiation.3 To determine if STAT5b-RAR is capable of binding to RAREs, in vitro translated STAT5b-RAR protein was examined by gel-shift assay using a series of RARE duplex oligonucleotides. As shown in Figure 1A, STAT5b-RAR alone bound to all RAREs tested and this binding could be competitively inhibited by 100-fold excess unlabeled RARE (Figure 1E). The shifted band corresponded to a homodimer of STAT5b-RAR with migration characteristics similar to PML-RAR and PLZF-RAR using RAR/RXR as a size reference (Figure 2A). The STAT5b-RAR homodimer binding preferences overall are similar to PML-RAR and PLZF-RAR (Figure 1A-C).30,31,40 However, a few slight differences in binding preferences were observed: STAT5b-RAR and PLZF-RAR bound to RARE-p21-WAF less efficiently than PML-RAR, and STAT5b-RAR bound to CRBPII and HOXA1 less efficiently than either PLZF-RAR or PML-RAR. View larger version (57K): [in this window] [in a new window]   Figure 1. RARE binding by homodimers of APL fusion proteins. Binding of homodimers of STAT5b-RAR (A), PML-RAR (B), and PLZF-RAR (C) and heterodimers of RAR/RXR (D) to a series of RAREs. Gel-shift assays were performed with in vitro translated proteins using the following radiolabeled probes: synthetic RARE, DR1, 2, 3, 4 and 5G,40 2 RARE (DR5T) from the human RARB gene,30 2 RARE from the human RARA gene,59 the natural enhancer elements from the rat cellular retinal-binding protein type I gene (CRBPI),60 the rat cellular retinal-binding protein type II gene (CRBPII),61 the murine cellular RA-binding protein gene (CRABPII),62 HOXA1 gene,63 HOXB1 gene64 and p21-WAF1 gene.65 Equivalent amounts of in vitro translated protein and labeled oligonucleotide were added to each binding reaction. The results of quantitative analysis using ImageQuant software are shown below each autoradiogram. In panel E, radiolabeled DR5G was incubated with in vitro translated STAT5b-RAR and the indicated fold excess unlabeled DR5G followed by gel-shift assay. View larger version (61K): [in this window] [in a new window]   Figure 2. RARE binding by heterodimers of APL fusion proteins. (A) Binding of heterodimers containing RXR and STAT5b-RAR, PLZF-RAR, PML-RAR, or wild-type RAR to 2 RAREs, DR5G and DR5T. (B) STAT5b-RAR/RXR heterodimer formation and RARE binding with increasing concentration of RXR. In vitro translated STAT5b-RAR protein (2.0 µL) was incubated without or with in vitro translated RXR protein (0, 0.05, 0.1, 0.2, 0.5, 1.0, and 2.5 µL). Gel-shift assays were performed using 2 RAREs, DR5G and DR5T. The location of the STAT5b-RAR homodimer band is indicated by the filled triangle; the location of the STAT5b-RAR/RXR heterodimer composed of one molecule of STAT5b-RAR plus one molecule of RXR is indicated by the unfilled triangle. The arrow indicates the position of the RXR homodimer binding to DR5G. (C) STAT5b-RAR/RXR heterodimer can bind a series of RAREs. STAT5b-RAR/RXR heterodimer is indicated by the filled triangle; RXR homodimer is indicated by the unfilled triangle. Very intriguingly, gel-shift assays containing both STAT5b-RAR and RXR resulted in the appearance of an additional prominent band (STAT5b-RAR/RXR heterodimer) with mobility characteristics intermediate between RAR/RXR heterodimer and STAT5b-RAR homodimer (Figure 2A). Increasing the amount of RXR while keeping the amount of STAT5b-RAR constant (Figure 2B) resulted in the disappearance of STAT5b-RAR homodimer band and increased the prominence of the STAT5b-RAR/RXR heterodimer band suggesting that STAT5b-RAR prefers to bind RARE as a heterodimer with RXR (one molecule of STAT5b-RAR plus one molecule of RXR) rather than as a homodimer. We and others have demonstrated previously30,31,40 and confirmed in this study (Figure 2A and data not shown) that when PML-RAR or PLZF-RAR binds RARE in combination with RXR, each does so as a single heterodimer as well as a higher order multimeric complex. In contrast, STAT5b-RAR and RXR bind RAREs virtually exclusively as a single heterodimer over a wide range of ratios and irrespective of the RARE (Figure 2C). The STAT5b coiled-coil domain is responsible for STAT5b-RAR homodimer formation and inhibition of RAR/RXR-mediated transcriptional activity STAT5b-RAR retains 3 complete domains of STAT5b, the N-terminal oligomerization domain, the coiled-coil domain, and the DNA-binding domain, in addition to a truncated SH2 domain (Figure 3A). The N-terminal and coiled-coil domains each have been demonstrated to mediate protein-protein interactions.11,41 To investigate whether or not either of these 2 domains or the DNA binding domain is important for the oncogenic functions of STAT5b-RAR, we compared the activities and functions of wild-type STAT5b-RAR with mutants of STAT5b-RAR in which the N-terminal, coiled-coil, or DNA-binding domain was deleted (Figure 3A). In gel-shift assays, STAT5b-RAR(N), STAT5b-RAR(DBD), and STAT5b-RAR(linker and part of SH2) each bound RARE alone as a homodimer or as a heterodimer with RXR (Figure 3B and data not shown). In contrast, STAT5b-RAR(CC) could not bind RARE as a homodimer, but rather it bound RARE only as a heterodimer with RXR. These findings indicate that the coiled-coil domain of STAT5b, and not the N-terminal or DNA-binding domains, is important for STAT5b-RAR homodimer formation. These results are reminiscent of those for PML-RAR in which the coiled-coil domain of PML was found to be responsible for the formation of PML-RAR homodimers.40,42,43 View larger version (33K): [in this window] [in a new window]   Figure 3. Requirement of the coiled-coil domain of STAT5b-RAR for RARE binding and transcription activation. (A) Schematic illustration of wild-type and mutated STAT5b-RAR constructs. (B) Gel-shift assays with wild-type and mutant STAT5b-RAR using 2 RAREs, DR5G and DR5T. (C) Transactivational activities of wild-type and mutant STAT5b-RAR in COS-7 cells. Following transfection with the indicated constructs, cells were cultured in medium with 106 M ATRA for 24 hours. Luciferase activity was normalized for transfection efficiency using a -galactosidase reporter plasmid. The results presented are the mean ± SD of triplicate wells and are representative of 3 separate experiments. Previously, PML-RAR and PLZF-RAR were demonstrated to have a dominant-negative effect on wild-type RAR/RXR transcriptional activity.3,5,29 To determine whether or not STAT5b-RAR behaves similarly, we examined the effect of STAT5b-RAR on RA-dependent, RAR/RXR-mediated transactivation of the RARE3-tk-luc reporter gene construct (Figure 3C). Transfection of the reporter construct alone or with RAR resulted in RA-dependent transactivation. Transfection with STAT5b-RAR alone or with RAR inhibited RA-dependent transactivation. Transfection of STAT5b-RAR(CC) did not inhibit but rather augmented RA-dependent RAR/RXR-mediated transcriptional activity similar to RAR, indicating that inhibition of RAR/RXR activity requires the coiled-coil domain of STAT5b-RAR and that in the absence of its coiled-coil domain, STAT5b-RAR functions like wild-type RAR. Effects of ATRA on the interaction of STAT5b-RAR with CoR SMRT and CoA TRAM-1 and on STAT5b-RAR protein degradation RAR/RXR and the APL fusion proteins PML-RAR and PLZF-RAR suppress transcription by associating with CoR and CoA depending on the concentration of ATRA.3 To determine the ATRA concentration dependence of the interactions of STAT5b-RAR with CoR and CoA, we examined the composition of complexes containing STAT5b-RAR, GST-SMRT, and GST-TRAM-1 in varying concentrations of ATRA (Figure 4A). SMRT dissociated from STAT5b-RAR at pharmacologic concentrations of ATRA (106 M) similar to that required for its dissociation from PML-RAR. This ATRA concentration is one log greater than that required to cause SMRT dissociation from RAR/RXR (107 M) and one log lower than that required for SMRT dissociation from PLZF-RAR (105 M). Immunoprecipitation assays (Figure 4B) demonstrated that although SMRT can form a complex with PLZF and RAR, as shown previously,25 it does not bind STAT5b. Complete recruitment of the CoA TRAM-1 to STAT5b-RAR occurred at 107 M ATRA similar to that for PLZF-RAR (Figure 4A), but one log greater that that for PML-RAR and RAR/RXR (108 M). View larger version (70K): [in this window] [in a new window]   Figure 4. Interactions of STAT5b-RAR, PML-RAR, and PLZF-RAR and wild-type RAR/RXR with the CoR SMRT and CoA TRAM-1. (A) The in vitro translated proteins indicated on the left were incubated with or without SMRT or TRAM-1 as indicated and the radiolabeled RARE, DR5G. The location of the complex containing the chimeric or wild-type receptor plus SMRT/TRAM-1 is indicated by the solid triangle; the location of the chimeric or wild-type receptor alone is indicated by the open triangle. (B) SDS-PAGE and autoradiography were performed on in vitro translated and 35S-methionine-labeled PLZF, RAR, or STAT5b alone or following incubation with SMRT and immunoprecipitation with SMRT antibody as indicated. The coiled-coil domain of PML-RAR APL fusion proteins contributes to the stability of the APL fusion protein/SMRT complex.26 To determine if this is the case for STAT5b-RAR, we examined the stability of the binding of in vitro translation proteins STAT5b-RAR and STAT5b-RAR(CC) with GST-SMRT in a GST pull-down assay under varying concentrations of ATRA (Figure 5A,B). STAT5b-RAR dissociated from GST-SMRT beginning at 106 M ATRA, whereas STAT5b-RAR(CC) dissociated from GST-SMRT beginning at 107 M ATRA, one log lower. These findings indicate that the coiled-coil domain plays an important role in the stability of STAT5b/SMRT-RAR complexes. View larger version (40K): [in this window] [in a new window]   Figure 5. Effect of ATRA on interactions STAT5b-RAR with GST-SMRT and on STAT5b-RAR stability. Radiolabeled wild-type or mutant STAT5b-RAR was incubated with GST-SMRT in the presence of the indicated concentrations of ATRA. After absorption with glutathione Sepharose, the proteins were separated and analyzed by autoradiography (A) and PhosphorImager analysis (B). COS-7 cells (C) and HeLa cells (D) were transiently transfected with STAT5b-RAR or PLZF-RAR and incubated without (lanes 1 and 3) or with (lanes 2 and 4) 106 M ATRA for 24 hours. Cells were lysed; proteins were separated by SDS-PAGE and immunoblotted with RAR antibody (upper panel) as well as -actin antibody (bottom panel), which was used as loading control. Densitometry analysis is presented below each immunoblot. The results shown are representative of up to 3 separate experiments. The empty triangle to the right of each upper panel indicates presumed proteolytic fragments of PLZF-RAR. Exposure to ATRA induces intracellular degradation of the PML-RAR and PLZF-RAR fusion proteins.44,45 We examined whether or not ATRA exposure similarly resulted in degradation of STAT5b-RAR. COS-7 and HeLa cells were transiently transfected with expression constructs containing STAT5b-RAR or PLZF-RAR and the cells incubated in 106 M ATRA for 24 hours. As previously described,44 PLZF-RAR protein levels sharply decreased in cells incubated with ATRA (Figure 5C,D). In contrast, the level of STAT5b-RAR protein in cells incubated with ATRA was virtually unchanged. STAT5b-RAR enhances STAT3 transcriptional activity but has no effect on STAT5 transcriptional activity Aberrant STAT3 activation has been demonstrated to occur in human leukemias and lymphomas,18 to be critical for v-Src transformation,46,47 and alone to be able to transform mouse and rat fibroblasts.41 To examine whether or not STAT5b-RAR modulated STAT3 activity, we used the HepG2 cell line in which the IL-6 receptor signaling pathway is intact together with an APRE-luciferase reporter gene construct.32 IL-6 exposure of HepG2 cells increased APRE-luciferase reporter gene activity 120-fold through the activation of endogenous STAT3 (Figure 6A and data not shown). This activation was inhibited 75% by cotransfection of HepG2 cells with STAT5b (Figure 6A, lane 2). Cotransfection of HepG2 cells with STAT5b-RAR augmented IL-6-induced reporter-construct activity 8-fold (Figure 6A, lane 3). In contrast, cotransfection with RAR had minimal effect. To assess whether or not the ability of STAT5b-RAR to augment STAT3 transcriptional activity is limited to STAT5b-RAR, we examined other APL fusion proteins in a similar fashion in HepG2 cells (Figure 6A, lanes 5 and 6). In addition to STAT5b-RAR, both PML-RAR and PLZF-RAR enhanced IL-6-mediated STAT3 transcriptional activity 8- to 26-fold. View larger version (25K): [in this window] [in a new window]   Figure 6. Effect of STAT5b-RAR and other APL fusion proteins on the STAT3 transcriptional and DNA binding activity. (A) Transactivation activities of STAT5b, STAT5b-RAR, RAR, PML-RAR, and PLZF-RAR in HepG2 cells. HepG2 cells were transiently transfected with 500 ng of APRE-luciferase reporter gene, 500 ng of -galactosidase expression vector, and 2.0 µg STAT5b, STAT5b-RAR, RAR, PML-RAR, and PLZF-RAR. Transfected cells were stimulated with IL-6 (25 ng/mL) for 24 hours. Luciferase activity was measured and normalized for transfection efficiency using a -galactosidase reporter construct. Data represent the mean ± SD of 5 separate experiments. The luciferase activity shown in lane 1 is increased 120-fold over the activity of identical cells incubated without IL-6 (not shown). (B) Gel-shift assays with WCEs from HepG2 cells transiently transfected with STAT5b or STAT5b-RAR. Transfected cells were incubated without or with IL-6 (25 ng/mL) for 30 minutes. The APRE (upper panel) and the hSIE (middle panel) were used as duplex oligonucleotide probes in this study. The location of the specific STAT3/DNA complex (upper panel and middle panel) and STAT5b/DNA (upper panel, lane 5) are indicated by the solid triangle and arrow, respectively; the empty triangle indicates the location of a nonspecific band. Levels of protein expression in the transiently transfected cells were determined by immunoblotting with the antibody against the N-terminal region of STAT5b (bottom panel). To begin to explore the mechanism of the enhanced STAT3 transcriptional activity, we assessed STAT3 DNA binding activity and Ser727 phosphorylation status in extracts of transfected versus nontransfected HepG2 cells. Cotransfection of STAT5b or STAT5b-RAR did not affect IL-6-stimulated binding to APRE or hSIE nor did it affect levels of Ser727 phosphorylation (Figure 6B and data not shown). Gene deletion mouse models48 and studies of dominant negative mutant constructs in cell lines49 support an important role for STAT5b in myeloid cell development. Consequently, the leukemogenic effect of STAT5b-RAR could also be mediated, in part, through its interference with normal STAT5b function. To investigate this possibility, we examined the effect of STAT5b-RAR on STAT5 activity downstream of the prolactin and IL-2Rs following reconstitution of these signaling pathways in COS-7 and 293T cells (Figure 7A and 7C). Transactivation of a reporter construct containing a -casein promoter was increased following transient transfection of prolactin receptor-reconstituted COS-7 and IL-2R-reconstituted 293T cells with STAT5b. Transient transfection of these cells with STAT5b-RAR, however, did not increase reporter construct activation nor did it inhibit the augmentation seen with transient overexpression of STAT5b. Similar results were obtained in IL-2R-reconstituted COS-7 cells (data not shown). In addition, transient coexpression of the fusion protein did not affect STAT5 DNA binding activity induced by prolactin in prolactin receptor-reconstituted COS-7 cells (Figure 7B) or by IL-2 in IL-2R-reconstituted COS-7 cells (Figure 7D). View larger version (48K): [in this window] [in a new window]   Figure 7. Effect of STAT5b-RAR on STAT5b transcriptional and DNA binding activity. (A) COS-7 cells were transiently transfected with the human prolactin receptor, a -casein-luciferase reporter gene construct, and STAT5b with or without STAT5b-RAR. Transfected cells were stimulated without or with ovine prolactin (500 ng/mL) for 24 hours. Luciferase activity was measured and normalized for transfection efficiency using a -galactosidase reporter construct. Data presented represent the mean ± SD of 3 separate experiments. (B) Gel-shift assays were performed using the PRE and WCEs of transiently transfected COS-7 cells that were incubated without or with prolactin (500 ng/mL) for 30 minutes. The location of the specific STAT5b/DNA complex is indicated with the solid triangle; a nonspecific band is indicated with the empty triangle. The level of protein expression, determined by immunoblotting with antibody against STAT5b, is shown in the bottom panel. (C) 293T cells were transiently transfected with the human -casein-luciferase reporter gene construct and expression constructs for IL-2R, C, Jak3, and STAT5b with or without STAT5b-RAR. Transfected cells were incubated without or with IL-2 (50 ng/mL) for 24 hours. Luciferase activity was measured and normalized for transfection efficiency using a -galactosidase reporter construct. Data presented represent the mean ± SD of 4 separate experiments. (D) Gel-shift assays were performed using the PRE and WCEs from IL-2R reconstituted and transiently transfected COS-7 cells that were incubated without or with IL-2 (50 ng/mL) for 30 minutes. The location of the specific STAT5b/DNA complex is indicated with the solid triangle; a nonspecific band is indicated with the empty triangle. The arrow indicates the position of the supershifted band. Levels of protein expression, determined by immunoblotting with antibody against STAT5b, are shown in the bottom panel for lanes 1 through 6.     Discussion Top Abstract Introduction Materials and methods Results Discussion References To understand the contribution to the pathogenesis of APL of a chromosomal abnormality resulting in a new RAR-containing fusion protein, it is necessary to evaluate several potential consequences of the abnormality including the effect of the resultant fusion protein on RAR function, the effect of the fusion protein on the function of the normal allele of the fusion partner, and the effect of the reciprocal fusion protein.3 In the studies outlined in this report, we demonstrated that STAT5b-RAR can bind RARE as a homodimer and can recruit SMRT. SMRT remained bound to STAT5b-RAR at physiologic concentrations of ATRA. Because STAT5b by itself did not bind SMRT, these findings suggest that the STAT5b portion of the fusion protein confers an allosteric change in the RAR portion of the fusion protein, similar to the non-RAR portions of other APL fusion proteins, thereby increasing its affinity for SMRT.3 This alone or together with the potential for each homodimer of STAT5b-RAR to bind 2 molecules of SMRT may result in superrepression of gene transcription by RAR/RXR.26,50 In addition to binding RARE as a homodimer, STAT5b-RAR preferentially bound RARE as a heterodimer with RXR. This feature is unique for STAT5b-RAR among APL fusion proteins and may contribute to its oncogenic potential by sequestering RXR and other essential transcription cofactors. The effect of the interstitial deletion and creation of the STAT5b-RAR on one allele of STAT5b has the effect of reducing by one half the amount of STAT5b expression. This by itself, however, would not be expected to affect myeloid development because deletion of both alleles of STAT5b in mice did not affect the myeloid lineage51 presumably because of its functional redundancy in myelopoiesis shared with STAT5a. The STAT5b portion of the fusion protein contains a truncated SH2 that includes the phosphotyrosine binding pocket.39 Consequently, STAT5b-RAR might retain the ability to bind activated STAT5a/b and act as a dominant negative. Our findings, however, that STAT5b-RAR did not affect ligand-induced STAT5 transcriptional activity or DNA binding activity do not support this possibility. Finally, because STAT5b-RAR was the result of an interstitial deletion, no reciprocal fusion protein was created. Recent evidence suggests that dimerization of PML-RAR is critically important for its oncogenic activity including inhibition of RA-mediated myeloid differentiation.26,42,43,50 Deletion of the coiled-coil domain within the PML portion of PML-RAR abrogated dimerization and relieved the inhibitory effects of the fusion protein on RA-induced differentiation.26,40,43 Similarly, we have demonstrated that the coiled-coil domain within the STAT5b portion of STAT5b-RAR is required for homodimerization in the presence of RARE, for its inhibitory effect on RAR/RXR transcriptional activity in COS-7 cells, and for its ability to stably interact with SMRT. Our results demonstrated that STAT5b-RAR augmented STAT3 transcriptional activity, whereas STAT5b inhibited it. Inhibition of STAT3 by STAT5b may be due to competition for binding to the APRE reporter construct coupled with the failure of STAT5b, relative to STAT3, to recruit the basal transcription machinery to the reporter construct. Alternatively, although STAT5b does not interact with the CoR SMRT, its ability to bind the APRE site and yet reduce transcriptional activity suggests it may bind and recruit another unidentified CoR. In addition to STAT5b-RAR, we demonstrated that other APL fusion proteins including PML-RAR and PLZF-RAR also had this enhancing effect on STAT3 transcriptional activity. STAT protein activation, especially STAT3, has been implicated in cell models of transformation and carcinogenesis. STAT3 was shown to be constitutively activated in cells transformed by oncoproteins such as v-Src.52,53 In addition, use of dominant-negative STAT3 constructs has shown that STAT3 is essential for fibroblast transformation by v-Src.46,47 Overexpression of a constitutively active form of STAT3 in immortalized rat or mouse fibroblasts induced their transformation and conferred the ability to form tumors in nude mice indicating that STAT3 alone can function as an oncogene.54 Aberrant activation of STAT3 also has been demonstrated in various human blood malignancies including leukemia and lymphoma.55-58 In each of these instances cited above, increased STAT3 activation was established in DNA binding assays. In our studies, however, the increased STAT3 transcriptional activity mediated by STAT5b-RAR was not accompanied by either increased STAT3 DNA binding activity or increased Ser727 phosphorylation. This result suggests that STAT5b-RAR and other APL fusion proteins participate in a novel mechanism of leukemogenesis involving enhanced STAT3 transcriptional activity independent of its DNA binding activity and Ser727 phosphorylation status. Based on its response to RA treatment, APL can be divided into 2 syndromes, RA-responsive APL, in which the RAR fusion gene partner is PML,5 NPM,7 or NuMA,8 and RA-resistant APL, in which the RAR fusion gene partner is PLZF9 or STAT5.10 Although it may be premature to designate STAT5b-RAR+ disease as RA unresponsive judging from only a single case,10 the RA response of the initial case of each of the other 3 APL variants reported has accurately reflected the RA response of subsequent cases within the variant group.3 To gain a molecular understanding of the ATRA unresponsiveness of STAT5b-RAR+ APL, we performed a series of studies intended, in part, to identify differences between STAT5b-RAR and PML-RAR, the most common fusion protein within the ATRA-responsive group, and to highlight similarities between STAT5b-RAR and PLZF-RAR, the sole other protein representative of the ATRA-unresponsive group. RARE-binding studies revealed that although the DNA-binding preferences of STAT5b-RAR homodimers resembled those of PML-RAR homodimers overall, STAT5b-RAR differed from PML-RAR and resembled PLZF-RAR in binding weakly to RARE-p21-WAF. Also, STAT5b-RAR and PLZF-RAR both required 107 M ATRA to fully recruit TRAM-1, whereas PML-RAR recruited TRAM-1 in 108 M ATRA. Our studies also identified features of STAT5b-RAR unique among APL fusion proteins. STAT5b-RAR differed from both PML-RAR and PLZF-RAR in that it heterodimerized with RXR almost exclusively as a single heterodimeric complex, whereas PML-RAR and PLZF-RAR heterodimerized with RXR and formed both single and multimeric complexes.30,40 Furthermore, STAT5b-RAR was insensitive to degradation within cells exposed to ATRA; although the importance of this finding is uncertain because PLZF-RAR is sensitive to ATRA-induced degradation yet results in ATRA-unresponsive disease. As outlined above, the finding that STAT5b can bind to and repress APRE reporter construct activity suggests that it may bind to a CoR distinct from SMRT. This raises the possibility that this CoR may remain bound to STAT5b-RAR in the presence of pharmacologic levels of ATRA and contribute to ATRA unresponsiveness in STAT5b-RAR+ APL.     Footnotes Submitted July 17, 2001; accepted November 19, 2001. Supported in part by National Institutes of Health R01 grants CA72261 and CA86430. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: David J. Tweardy, Section of Infectious Disease, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, BCM 286, Rm N1319, Houston, TX 77030; e-mail: dtweardy{at}bcm.tmc.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064[Abstract/Free Full Text]. 2. Chen Z, Tong JH, Dong S, Zhu J, Wang ZY, Chen SJ. Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Genes Chromosomes Cancer. 1996;15:147-156[CrossRef][Medline] [Order article via Infotrieve]. 3. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215[Free Full Text]. 4. Warrell RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189[Free Full Text]. 5. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684[CrossRef][Medline] [Order article via Infotrieve]. 6. Dong S, Geng JP, Tong JH, et al. Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17). Genes Chromosomes Cancer. 1993;6:133-139[Medline] [Order article via Infotrieve]. 7. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996;87:882-886[Abstract/Free Full Text]. 8. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997;17:109-113[CrossRef][Medline] [Order article via Infotrieve]. 9. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 1993;12:1161-1167[Medline] [Order article via Infotrieve]. 10. Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8:1741-1749[Abstract/Free Full Text]. 11. Darnell JE. STATs and gene regulation. Science. 1997;277:1630-1635[Abstract/Free Full Text]. 12. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293-322[CrossRef][Medline] [Order article via Infotrieve]. 13. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 1994;13:2182-2191[Medline] [Order article via Infotrieve]. 14. Wegenka UM, Lutticken C, Buschmann J, et al. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol. 1994;14:3186-3196[Abstract/Free Full Text]. 15. Shi W, Inoue M, Minami M, et al. The genomic structure and chromosomal localization of the mouse STAT3 gene. Int Immunol. 1996;8:1205-1211[Abstract/Free Full Text]. 16. Lin JX, Mietz J, Modi WS, John S, Leonard WJ. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem. 1996;271:10738-10744[Abstract/Free Full Text]. 17. Copeland NG, Gilbert DJ, Schindler C, et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics. 1995;29:225-228[CrossRef][Medline] [Order article via Infotrieve]. 18. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-2488[CrossRef][Medline] [Order article via Infotrieve]. 19. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940-954[Abstract]. 20. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377:454-457[CrossRef][Medline] [Order article via Infotrieve]. 21. Kurokawa R, Soderstrom M, Horlein A, et al. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature. 1995;377:451-454[CrossRef][Medline] [Order article via Infotrieve]. 22. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997;90:569-580[CrossRef][Medline] [Order article via Infotrieve]. 23. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270:1354-1357[Abstract/Free Full Text]. 24. Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW. TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem. 1997;272:27629-27634[Abstract/Free Full Text]. 25. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811-814[CrossRef][Medline] [Order article via Infotrieve]. 26. Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell. 2000;5:821-830[CrossRef][Medline] [Order article via Infotrieve]. 27. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126-135[CrossRef][Medline] [Order article via Infotrieve]. 28. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood. 1997;89:4282-4289[Abstract/Free Full Text]. 29. Chen Z, Guidez F, Rousselot P, et al. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A. 1994;91:1178-1182[Abstract/Free Full Text]. 30. Dong S, Zhu J, Reid A, et al. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger- retinoic acid receptor-alpha fusion protein. Proc Natl Acad Sci U S A. 1996;93:3624-3629[Abstract/Free Full Text]. 31. So CW, Dong S, So CK, et al. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. Leukemia. 2000;14:77-83[CrossRef][Medline] [Order article via Infotrieve]. 32. Daino H, Matsumura I, Takada K, et al. Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells. Blood. 2000;95:2577-2585[Abstract/Free Full Text]. 33. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem. 1999;274:22484-22492[Abstract/Free Full Text]. 34. John S, Vinkemeier U, Soldaini E, Darnell JE, Leonard WJ. The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol. 1999;19:1910-1918[Abstract/Free Full Text]. 35. Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, Leonard WJ. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol. 2000;20:389-401[Abstract/Free Full Text]. 36. Zhu M, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell. 1999;96:121-130[CrossRef][Medline] [Order article via Infotrieve]. 37. Yon J, Fried M. Precise gene fusion by PCR. Nucleic Acids Res. 1989;17:4895[Free Full Text]. 38. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989. 39. Chakraborty A, Dyer KF, Cascio M, Mietzner TA, Tweardy DJ. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood. 1999;93:15-24[Abstract/Free Full Text]. 40. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 1993;12:3171-3182[Medline] [Order article via Infotrieve]. 41. Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19:2468-2473[CrossRef][Medline] [Order article via Infotrieve]. 42. Grignani F, Testa U, Rogaia D, et al. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J. 1996;15:4949-4958[Medline] [Order article via Infotrieve]. 43. Grignani F, Gelmetti V, Fanelli M, et al. Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response. Oncogene. 1999;18:6313-6321[CrossRef][Medline] [Order article via Infotrieve]. 44. Koken MH, Reid A, Quignon F, et al. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci U S A. 1997;94:10255-10260[Abstract/Free Full Text]. 45. Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A. 1999;96:14807-14812[Abstract/Free Full Text]. 46. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol. 1998;18:2553-2558[Abstract/Free Full Text]. 47. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18:2545-2552[Abstract/Free Full Text]. 48. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841-850[CrossRef][Medline] [Order article via Infotrieve]. 49. Ilaria RL, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood. 1999;93:4154-4166[Abstract/Free Full Text]. 50. Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000;5:811-820[CrossRef][Medline] [Order article via Infotrieve]. 51. Imada K, Bloom ET, Nakajima H, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med. 1998;188:2067-2074[Abstract/Free Full Text]. 52. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81-83[Abstract/Free Full Text]. 53. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci. 1998;5:79-85[Medline] [Order article via Infotrieve]. 54. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98:295-303[CrossRef][Medline] [Order article via Infotrieve]. 55. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312[Abstract/Free Full Text]. 56. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999;189:1229-1242[Abstract/Free Full Text]. 57. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247-254[Medline] [Order article via Infotrieve]. 58. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 1998;58:3173-3180[Abstract/Free Full Text]. 59. Leroy P, Nakshatri H, Chambon P. Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element. Proc Natl Acad Sci U S A. 1991;88:10138-10142[Abstract/Free Full Text]. 60. Husmann M, Hoffmann B, Stump DG, Chytil F, Pfahl M. A retinoic acid response element from the rat CRBPI promoter is activated by an RAR/RXR heterodimer. Biochem Biophys Res Commun. 1992;187:1558-1564[CrossRef][Medline] [Order article via Infotrieve]. 61. Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, Evans RM. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell. 1991;66:555-561[CrossRef][Medline] [Order article via Infotrieve]. 62. Durand B, Saunders M, Leroy P, Leid M, Chambon P. All-trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. Cell. 1992;71:73-85[CrossRef][Medline] [Order article via Infotrieve]. 63. Frasch M, Chen X, Lufkin T. Evolutionary-conserved enhancers direct region-specific expression of the murine Hoxa-1 and Hoxa-2 loci in both mice and Drosophila. Development. 1995;121:957-974[Abstract]. 64. Mendelsohn C, Ruberte E, LeMeur M, Morriss-Kay G, Chambon P. Developmental analysis of the retinoic acid-inducible RAR-beta 2 promoter in transgenic animals. Development. 1991;113:723-734[Abstract]. 65. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem. 1996;271:31723-31728[Abstract/Free Full Text]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Benekli, H. Baumann, and M. Wetzler Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias J. Clin. Oncol., September 10, 2009; 27(26): 4422 - 4432. [Abstract] [Full Text] [PDF] S. Wang, G. Tricot, L. Shi, W. Xiong, Z. Zeng, H. Xu, M. Zangari, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan RAR{alpha}2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma Blood, July 16, 2009; 114(3): 600 - 607. [Abstract] [Full Text] [PDF] B. Sen, B. Saigal, N. Parikh, G. Gallick, and F. M. Johnson Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding Cancer Res., March 1, 2009; 69(5): 1958 - 1965. [Abstract] [Full Text] [PDF] Y. Huang, J. Qiu, S. Dong, M. S. Redell, V. Poli, M. A. Mancini, and D. J. Tweardy Stat3 Isoforms, {alpha} and , Demonstrate Distinct Intracellular Dynamics with Prolonged Nuclear Retention of Stat3 Mapping to Its Unique C-terminal End J. Biol. Chem., November 30, 2007; 282(48): 34958 - 34967. [Abstract] [Full Text] [PDF] J. Qiu, Y. Huang, G. Chen, Z. Chen, D. J. Tweardy, and S. Dong Aberrant Chromatin Remodeling by Retinoic Acid Receptor {alpha} Fusion Proteins Assessed at the Single-Cell Level Mol. Biol. Cell, October 1, 2007; 18(10): 3941 - 3951. [Abstract] [Full Text] [PDF] X. Liu, Q. Shi, and C. D. Sigmund Interleukin-1{beta} Attenuates Renin Gene Expression Via a Mitogen-Activated Protein Kinase Kinase-Extracellular Signal-Regulated Kinase and Signal Transducer and Activator of Transcription 3-Dependent Mechanism in As4.1 Cells Endocrinology, December 1, 2006; 147(12): 6011 - 6018. [Abstract] [Full Text] [PDF] C. W. So and M. L. Cleary Dimerization: a versatile switch for oncogenesis Blood, August 15, 2004; 104(4): 919 - 922. [Abstract] [Full Text] [PDF] S. Dong, D. L. Stenoien, J. Qiu, M. A. Mancini, and D. J. Tweardy Reduced Intranuclear Mobility of APL Fusion Proteins Accompanies Their Mislocalization and Results in Sequestration and Decreased Mobility of Retinoid X Receptor {alpha} Mol. Cell. Biol., May 15, 2004; 24(10): 4465 - 4475. [Abstract] [Full Text] [PDF] Y. Tabe, M. Konopleva, M. F. Munsell, F. C. Marini, C. Zompetta, T. McQueen, T. Tsao, S. Zhao, S. Pierce, J. Igari, et al. PML-RAR{alpha} is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival Blood, March 1, 2004; 103(5): 1815 - 1822. [Abstract] [Full Text] [PDF] D. W. Sternberg and D. G. Gilliland The Role of Signal Transducer and Activator of Transcription Factors in Leukemogenesis J. Clin. Oncol., January 15, 2004; 22(2): 361 - 371. [Abstract] [Full Text] [PDF] J. A. Kelly, R. Spolski, P. E. Kovanen, T. Suzuki, J. Bollenbacher, C. A. Pise-Masison, M. F. Radonovich, S. Lee, N. A. Jenkins, N. G. Copeland, et al. Stat5 Synergizes with T Cell Receptor/Antigen Stimulation in the Development of Lymphoblastic Lymphoma J. Exp. Med., July 7, 2003; 198(1): 79 - 89. [Abstract] [Full Text] [PDF] A. Rascle, J. A. Johnston, and B. Amati Deacetylase Activity Is Required for Recruitment of the Basal Transcription Machinery and Transactivation by STAT5 Mol. Cell. Biol., June 15, 2003; 23(12): 4162 - 4173. [Abstract] [Full Text] [PDF] A. Kawasaki, I. Matsumura, Y. Kataoka, E. Takigawa, K. Nakajima, and Y. Kanakura Opposing effects of PML and PML/RARalpha on STAT3 activity Blood, May 1, 2003; 101(9): 3668 - 3673. [Abstract] [Full Text] [PDF] M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler Signal transducer and activator of transcription proteins in leukemias Blood, April 15, 2003; 101(8): 2940 - 2954. [Abstract] [Full Text] [PDF] M. L. Clabby, T. A. Robison, H. F. Quigley, D. B. Wilson, and D. P. Kelly Retinoid X Receptor alpha Represses GATA-4-mediated Transcription via a Retinoid-dependent Interaction with the Cardiac-enriched Repressor FOG-2 J. Biol. Chem., February 14, 2003; 278(8): 5760 - 5767. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dong, S. Articles by Tweardy, D. J. Search for Related Content PubMed PubMed Citation Articles by Dong, S. Articles by Tweardy, D. J. Related Collections Neoplasia Plenary Papers Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020